OFIX
BEARISH
$12.87
Live
Orthofix Medical Inc. · NASDAQ
Target $17.25
(+34.0%)
$10.24
52W Range
$16.99
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 16, 2026
Market cap
$516.66M
P/E
N/A
ROE
-19.3%
Profit margin
-11.2%
Debt/Equity
0.45
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
OFIX exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor operational health. While the company maintains a strong gross margin and a healthy current ratio, these are offset by negative profit margins and stagnant revenue growth of only 2%. The long-term price trajectory is devastating, with a 5-year decline of 70.9%, and insider sentiment is decidedly bearish with consistent selling. Despite optimistic analyst price targets, the high PEG ratio of 8.48 suggests the stock is significantly overvalued relative to its actual growth profile.
Key Strengths
Strong gross margin of 68.83%
Healthy liquidity with a current ratio of 2.44
Manageable leverage with a Debt/Equity ratio of 0.45
Consistent history of beating low earnings estimates
Positive analyst consensus with a target price of $17.25
Key Risks
Critically low Piotroski F-Score (2/9) signaling financial deterioration
Stagnant revenue growth (2.00% YoY) failing to drive expansion
Negative profitability (Profit Margin -11.21%, ROE -19.34%)
Strong bearish insider signal with 10 sell transactions and 0 buys
Severe long-term value destruction (5Y change of -70.9%)
AI Fair Value Estimate
Based on comprehensive analysis
$11.5
-10.6% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
23
Weak
40
30
20
25
0
AI Verdict
High Risk / Speculative
Key drivers: Poor Piotroski F-Score, Negative net margins, Bearish insider activity, Stagnant top-line growth
Confidence
90%
Value
40/100
Forward P/E of 15.05 is misleading given the lack of growth and negative current margins.
Positives
- Low Price/Sales (0.63)
- Price/Book near 1.14
Watchpoints
- Extremely high PEG ratio (8.48)
- Negative earnings
Future
30/100
Growth metrics do not justify the current valuation premium.
Positives
- Analyst target price suggests 34% upside
Watchpoints
- Revenue growth is nearly flat at 2%
- Negative ROE indicates poor capital utilization
Past
20/100
Historical trend shows a persistent inability to create shareholder value.
Positives
- Recent quarterly earnings beats
Watchpoints
- 5-year price collapse of 70.9%
- Consistent failure to maintain positive net income
Health
25/100
Strong balance sheet liquidity is being wasted by poor operational efficiency.
Positives
- Low Debt/Equity (0.45)
- Strong Current Ratio (2.44)
Watchpoints
- Piotroski F-Score of 2/9 is a major red flag
Dividend
0/100
Dividend strength is 0/100.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$12.87
Analyst Target
$17.25
Upside/Downside
+34.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for OFIX and closest competitors.
Updated 2026-04-15
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
OFIX
Orthofix Medical Inc.
Primary
|
-70.9% | -30.2% | -4.0% | -14.4% | +8.4% | +5.5% |
|
NPCE
NeuroPace, Inc.
Peer
|
-38.5% | +219.8% | +43.9% | +41.9% | +8.2% | +5.8% |
|
PIII
P3 Health Partners Inc.
Peer
|
-99.5% | -95.6% | -74.5% | -72.2% | -4.2% | -5.3% |
|
EMBC
Embecta Corp.
Peer
|
-78.3% | -65.2% | -18.7% | -34.0% | -3.8% | +1.0% |
|
MCTA
Charming Medical Limited
Peer
|
+319.4% | +319.4% | +319.4% | +319.4% | 0.0% | 0.0% |
OFI
Orthofix Medical Inc.
Primary
5Y
-70.9%
3Y
-30.2%
1Y
-4.0%
6M
-14.4%
1M
+8.4%
1W
+5.5%
NPC
NeuroPace, Inc.
Peer
5Y
-38.5%
3Y
+219.8%
1Y
+43.9%
6M
+41.9%
1M
+8.2%
1W
+5.8%
PII
P3 Health Partners Inc.
Peer
5Y
-99.5%
3Y
-95.6%
1Y
-74.5%
6M
-72.2%
1M
-4.2%
1W
-5.3%
EMB
Embecta Corp.
Peer
5Y
-78.3%
3Y
-65.2%
1Y
-18.7%
6M
-34.0%
1M
-3.8%
1W
+1.0%
MCT
Charming Medical Limited
Peer
5Y
+319.4%
3Y
+319.4%
1Y
+319.4%
6M
+319.4%
1M
0.0%
1W
0.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
15.05
PEG Ratio
8.48
P/B Ratio
1.14
P/S Ratio
0.63
EV/Revenue
0.78
EV/EBITDA
-103.87
Market Cap
$516.66M
Profitability
Profit margins and return metrics
Profit Margin
-11.21%
Operating Margin
-1.27%
Gross Margin
68.83%
ROE
-19.34%
ROA
-4.91%
Growth
Revenue and earnings growth rates
Revenue Growth
+2.0%
Earnings Growth
N/A
Q/Q Revenue Growth
+1.97%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.45
Low debt
Current Ratio
2.44
Strong
Quick Ratio
1.28
Good
Cash/Share
$2.04
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.2B
Gross Margin
71.1%
Op. Margin
0.5%
Net Margin
-1.0%
Total Assets
$0.9B
Liabilities
$0.4B
Equity
$0.5B
Debt/Equity
0.89x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
61%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-24
$0.24
-42.7% surprise
2025-11-04
$0.2
+64.7% surprise
2025-08-05
$0.13
+223.5% surprise
Healthcare Sector Comparison
Comparing OFIX against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
Return on Equity (ROE)
-19.34%
This Stock
vs
-100.15%
Sector Avg
-80.7%
(Below Avg)
Profit Margin
-11.21%
This Stock
vs
-13.63%
Sector Avg
-17.7%
(Weaker)
Debt to Equity
0.45
This Stock
vs
3.22
Sector Avg
-85.9%
(Less Debt)
Revenue Growth
2.0%
This Stock
vs
121.05%
Sector Avg
-98.3%
(Slower)
Current Ratio
2.44
This Stock
vs
4.55
Sector Avg
-46.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
OFIX
Orthofix Medical Inc.
|
BEARISH | $516.66M | - | -19.3% | -11.2% | $12.87 | |
|
NPCE
NeuroPace, Inc.
|
NEUTRAL | $516.79M | - | -158.7% | -21.5% | $15.35 | Compare |
|
PIII
P3 Health Partners Inc.
|
BEARISH | $507.93M | - | -6952.6% | -10.1% | $2.5 | Compare |
|
EMBC
Embecta Corp.
|
NEUTRAL | $525.87M | 3.73 | -% | 12.9% | $8.88 | Compare |
|
MCTA
Charming Medical Limited
|
BEARISH | $504.26M | 419.36 | -% | 12.1% | $29.36 | Compare |
OFIX
Orthofix Medical Inc.
BEARISH
Mkt Cap
$517M
P/E
-
ROE
-19.3%
Price
$12.87
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-17 | VITALE LUCAS S | Chief Operating Officer | Sale | 4,269 | $50,886 |
| 2026-03-10 | CAPPS VICKIE LYNN | Director | Purchase | 5,000 | $62,324 |
| 2026-03-05 | ANDREWS JULIE | Chief Financial Officer | Sale | 4,788 | $60,980 |
| 2026-03-05 | FISHER PATRICK G | Officer | Sale | 1,536 | $19,562 |
| 2026-03-05 | VITALE LUCAS S | Chief Operating Officer | Sale | 2,312 | $29,445 |
| 2026-03-05 | REINHARDT MAX | Officer | Sale | 2,133 | $27,166 |
| 2026-03-05 | CALAFIORE MASSIMO | Chief Executive Officer | Sale | 12,220 | $155,633 |
| 2026-03-05 | CEDRON JORGE ANDRES | Officer | Sale | 2,775 | $35,342 |
| 2026-03-05 | MCPHERRON AVIVA | Officer | Sale | 2,559 | $32,591 |
| 2026-03-03 | ANDREWS JULIE | Chief Financial Officer | Stock Award | 35,495 | - |
| 2026-03-03 | FISHER PATRICK G | Officer | Stock Award | 21,105 | - |
| 2026-03-03 | VITALE LUCAS S | Officer | Stock Award | 19,186 | - |
| 2026-03-03 | CALAFIORE MASSIMO | Chief Executive Officer | Stock Award | 115,119 | - |
| 2026-03-03 | CEDRON JORGE ANDRES | Officer | Stock Award | 23,024 | - |
| 2026-03-03 | MCPHERRON AVIVA | Officer | Stock Award | 23,024 | - |
VITALE LUCAS S
Chief Operating Officer
2026-03-17
4,269 shares
·
$50,886
CAPPS VICKIE LYNN
Director
2026-03-10
5,000 shares
·
$62,324
ANDREWS JULIE
Chief Financial Officer
2026-03-05
4,788 shares
·
$60,980
FISHER PATRICK G
Officer
2026-03-05
1,536 shares
·
$19,562
VITALE LUCAS S
Chief Operating Officer
2026-03-05
2,312 shares
·
$29,445
REINHARDT MAX
Officer
2026-03-05
2,133 shares
·
$27,166
CALAFIORE MASSIMO
Chief Executive Officer
2026-03-05
12,220 shares
·
$155,633
CEDRON JORGE ANDRES
Officer
2026-03-05
2,775 shares
·
$35,342
MCPHERRON AVIVA
Officer
2026-03-05
2,559 shares
·
$32,591
ANDREWS JULIE
Chief Financial Officer
2026-03-03
35,495 shares
FISHER PATRICK G
Officer
2026-03-03
21,105 shares
VITALE LUCAS S
Officer
2026-03-03
19,186 shares
CALAFIORE MASSIMO
Chief Executive Officer
2026-03-03
115,119 shares
CEDRON JORGE ANDRES
Officer
2026-03-03
23,024 shares
MCPHERRON AVIVA
Officer
2026-03-03
23,024 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
4 analysts
Barrington Research
2026-04-10
Outperform
Outperform
Stifel
2026-03-09
Buy
Buy
Canaccord Genuity
2026-02-26
Buy
Buy
Barrington Research
2026-02-25
Outperform
Outperform
Barrington Research
2026-02-17
Outperform
Outperform
TD Cowen
2026-01-27
Hold
Barrington Research
2025-11-05
Outperform
Outperform
Barrington Research
2025-10-23
Outperform
Outperform
Past News Coverage
Recent headlines mentioning OFIX from our newsroom.
Newest → oldest
No matching news yet.